Clinical data | |
---|---|
Trade names | Vistaril , Atarax |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682866 |
Pregnancy category |
|
Routes of administration |
Oral, IM |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High in-vivo |
Protein binding | 93% |
Metabolism | Hepatic |
Biological half-life | 20–24 hours |
Excretion | Urine, Feces |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.000.630 |
Chemical and physical data | |
Formula | C21H27ClN2O2 |
Molar mass | 374.904 g/mol |
3D model (Jmol) | |
|
|
|
|
Hydroxyzine (/haɪˈdrɒksᵻziːn/) is a first-generation antihistamine of the diphenylmethane and piperazine class. It was first synthesized by Union Chimique Belge in 1956 and was marketed by Pfizer in the United States later the same year, and is still in widespread use today.
Due to its antagonistic effects on several receptor systems in the brain, hydroxyzine has strong anxiolytic and mild antiobsessive as well as antipsychotic properties. Today it is used primarily for the symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Because of its antihistamine effects it can also be used for the treatment of severe cases of itching, hyperalgesia and motion sickness-induced nausea; it has also been used in some cases to relieve the effects of opioid withdrawal. Even though it is an effective sedative, hypnotic, and anxiolytic, it shares virtually none of the abuse, dependence, addiction, and toxicity potential of other drugs used for the same range of therapeutic reasons. Hydroxyzine has also been used to potentiate the analgesia of opioids and to alleviate some of their side effects, such as itching, nausea, and vomiting.